"Designing Growth Strategies is in our DNA"

Psoriasis Treatment Market Size, Share and Global Trend By Drug Class (TNF Inhibitors, Interleukins, Others), By Type (Plaque Psoriasis, Psoriatic Arthritis, Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online pharmacies), and Geography Forecast till 2026

Region : Global | Published Date: Jul, 2019 | Report ID: FBI100600| Status : Published

 

KEY INDUSTRY INSIGHTS

Global Psoriasis Treatment Market Was Valued at US$ 18,378.0 Mn in 2018 and is Projected to Reach US$ 37,634.2 Mn by 2026, Exhibiting a CAGR of 8.2% during the forecast period. Psoriasis is a common, chronic, non-communicable skin disease, with no clear cause or cure. It is an autoimmune inflammatory disorder resulting in overproduction of skin cells, leading to an itchy and painful skin condition characterized by inflammation, red lesions, and plaques formation on the skin. It can occur at any age and is most common in the age group from 50 to 70 years.

According to the World Health Organization (WHO), the prevalence of psoriasis is estimated to vary between 0.09% to 11.0% across all nations, making psoriasis a serious global problem. In most of the developed countries, the prevalence of psoriasis is between 1.5 to 5.0%, and an upward trend in the disease prevalence has been observed in recent years. The disease can be categorized in to two major types, plaque psoriasis, and psoriatic arthritis. According to a study published by Celgene Corporation, about 30% of the patients with psoriasis develop inflammatory condition of joints, known as psoriatic arthritis.

Get comprehensive study about this report by, request a sample copy

Rapidly increasing geriatric population, growing prevalence of plaque psoriasis and psoriatic arthritis, the huge pipeline of biologic and biosimilar products, favorable reimbursement policies, and growing prescription volume of the biologic products are some of the major factors contributing the psoriasis treatment market growth.

Key Market Drivers

Growing prevalence of psoriasis, surge in biological therapy approvals, recent changes in the treatment guidelines, growing adoption of novel biologicals, and increase in the healthacre awareness leading to early diagnosis of the disease are projected to augment the psoriasis treatment market growth during the forecast period.

The rise in the prevalence of psoriasis around the globe has upsurged the demand for safe and effective therapies for the treatment of psoriasis. According to the National Psoriasis Foundation (NPF), it is estimated that in 2017, around 125 million people globally had psoriasis, out of which 10-20% population developed psoriasis arthritis. Moreover, a recent wave of biologicals in the treatment of psoriatic conditions is likely to double the psoriasis treatment market by the end of 2026 leveraging a great market potential for investment in the novel product developments and clinical trials. A wide opportunity for many key players to enter the global to launch new products through investments in research and development activities. Additionally, growing strategic collaborations and mergers among various key players in the psoriasis treatment market are increasing the penetration of innovative products. For instance, in February 2018, UCB S.A. presented its new data on CIMZIA, and another key pipeline molecule, bimekizumab, at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, CA. This data demonstrated positive treatment results of CIMZIA in adults with the moderate-to-severe chronic plaque psoriasis. However, the market faces some of the major challenges such as limited penetration of biologics in emerging regions due to the high cost of products, delay in diagnosis, gaps in clinical management, and lack of consensus on treatment outcomes, which are likely to hamper the growth of the psoriasis treatment market during the analysis period.

Market Segmentation

Based on drug class, the global psoriasis treatment market segments include TNF Inhibitors, interleukin inhibitors, and others. Among them, the TNF inhibitors segment dominated the market, holding a share of 46.3% in the year 2018. The segment is expected to lose the market share owing to the decline in the prices of branded products resulted in from the entry of biosimilar versions and growing prescription volume for interleukin inhibitors segment. Plaque psoriasis segment dominated the market; however, growing applications of biologics in the management of psoriatic arthritis is likely to push the growth of psoriatic arthritis segment significantly during the forecast period.

To get details on market share, speak to our analyst

Regional Analysis

Easy access to medical care in the U.S., high prescription volume of biologics, high cost of the biologic products, and growing prevalence of psoriasis in the region contribute to the dominance of North America region in the global psoriasis treatment market

The growing burden of psoriasis in the North American countries is likely to drive the demand for the novel and effective treatment options for management of the condition. According to the National Psoriasis Foundation, currently, about 8 million Americans are living with psoriasis. The region is likely to continue its dominance throughout the forecast period and this is attributable to high adoption of biological therapies, high research and development spending by the players in the region on clinical trials on psoriasis management, and increase in long-term & preventive healthcare facilities. Development of strong healthcare reforms in the U.S. will provide psoriasis patients with greater accessibility to medical care, which, in turn, will fuel the psoriasis treatment market growth during the forecast period. Europe was the second largest market for psoriasis treatment while Asia Pacific is projected to expand at the highest growth rate during the forecast period. Latin America and the Middle East & Africa regions are considered to be the emerging markets leveraging a great opportunity for the players willing to establish their footprints in these regions.

North America Psoriasis Treatment Market Size, 2018

To get geographical overview of this market, request a sample copy

Key Players

Psoriasis treatment market is a fairly consolidated market with industry behemoths holding major chunk of the market. AbbVie held leading position with its leading brand Humira which is still the most prescribed biologic for the management of psoriasis. Moreover, the company recently got an approval for Skyrizi (risankizumab) for the treatment of psoriasis patients on 23 April 2019. Other leading players in the psoriasis treatment market includes industry giants such as Novartis AG, Pfizer Inc., Amgen, Merck etc.

Report Coverage

The report provides qualitative and quantitative insights on psoriasis treatment industry trends and detailed analysis of market size & growth rate for all possible segments in the market. The psoriasis treatment market segments include drug class, type, route of administration, and distribution channel. Based on drug class, the global psoriasis treatment market is segmented into TNF inhibitors, interleukin inhibitors, and others. Based on type, the global psoriasis treatment market is segmented into plaque psoriasis and psoriatic arthritis. In terms of route of administration, the market is categorized into oral, parenteral, and topical. Based on distribution channel, the global psoriasis treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The regions are further categorized into countries.

Along with this, the report analysis comprises of market dynamics and competitive landscape. Additionally, the report offers insights on the prevalence of psoriasis and psoriatic arthritis for key countries/region, recent industry developments such as partnerships, mergers & acquisitions, new product launches etc.; pipeline analysis for key companies, regulatory framework by key countries, and global reimbursement scenario.

To get information on various segments, share your queries with us

SEGMENTATION

SEGMENTATION

DETAILS

By Drug Class

· TNF Inhibitors

· Interleukins

· Others

By Type

· Plaque Psoriasis

· Psoriatic Arthritis

· Others

By Route of Administration

· Oral

· Parenteral

· Topical

By Distribution Channel

· Hospital Pharmacies

· Retail Pharmacies

· Online pharmacies

By Geography

· North America (U.S. and Canada)

· Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

· Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

· Latin America (Brazil, Mexico, and Rest of Latin America)

· Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)

Psoriasis Treatment Market, Key Players

  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.,
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Amgen Inc.
  • Eli Lilly and Company 
  • CELGENE CORPORATION
  • UCB S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Other prominent players

Key Industry Developments

  • In May 2019, Mayne Pharma Group Limited received FDA approval to use SORILUX Foam for the treatment of plaque psoriasis of the body & scalp in patients aged 12 years and older.
  • In April 2019, Ortho Dermatologics received FDA approval to use Duobrii (halobetasol propionate and tazarotene) which is the first and currently only lotion indicated for adults with plaque psoriasis by limiting the overgrowth of cells responsible for plaque psoriasis formation.
  • In February 2019, Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services, Inc.) received FDA approval to use TREMFYA, One-Press, a single-dose, patient-controlled injector for the treatment of moderate-to-severe plaque psoriasis in adults.
  • In December, 2017, Pfizer Inc. announced that USFDA has approved its product Infliximab, a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.1

Psoriasis Treatment Market Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2018
  • 2015-2017
  • 155

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X